Comment on Zenith, Question for bengtpressHave just been browsing through the past week of comments (quite a few!) so may have missed a few but it seems to me that McCaffrey sounded pretty relaxed on the cc for a guy who some think has little to bargain with and is running out of money. Could there possibly be a deal in the works for locking RVX up which would in turn fund Zenith for some time. On a CVR I don't think $200 million upfront for RVX-208 is an outrageous number and that would put $16 million into Zenith. I know this is "positive thinking" but I think the downside has, not unwarrantly so, been fairly thoroughly explored.
Bengtpress you mentioned in your comments in answer to JDstox that you felt in a CVR deal there was potentially 30-40 dollars per share rights money for RVX shareholders should RVX-208 be successful. What do you base this guess on? On the surface if RVX-208 was successful even for only 8 years of patent protected revenue there would be more than enough cash flow to produce numbers that would support this but do you think that this much room would be left on the table by a pharma. Perhaps under a competitive situation and royalties are almost a no risk pledge. Just curious as to your thoughts behind this guess. Thanks